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ABSTRACT 
Background: Highly effective direct-acting antiviral (DAA) regimens (90% efficacy)are becoming 
available for hepatitis C virus (HCV) treatment. This therapeutic revolution leads us to consider 
possibility of eradicating the virus. However, for this, an effective cascade of care is required.  
Methods: In the context of the incoming DAAs,we used a dynamic individual-based model including a 
model of the people who inject drugs (PWID) social network to simulate the impact of improved 
testing, linkage to care, and adherence to treatment, and of modified treatment recommendation on the 
transmission and on the morbidity of HCV in PWID in France.  
Results: Under the current incidence and cascade of care, with treatment initiated at fibrosis stage 
≥F2,the HCV prevalence decreased from 42.8% to 24.9% [95% confidence interval 24.8%–24.9%] 
after 10 years. Changing treatment initiation criteria to treat from F0 was the only intervention leading 
to a substantial additional decrease in the prevalence, which fell to 11.6% [11.6%–11.7%] at 10 years. 
Combining this change with improved testing, linkage to care, and adherence to treatment decreased 
HCV prevalence to 7% [7%–7.1%] at 10 years and avoided 15.3% [14.0%-16.6%] and 29.0% 
[27.9%–30.1%] of cirrhosis complications over 10 and 40 years respectively.  
Conclusion: A high decrease in viral transmission occurs only when treatment is initiated before liver 
disease progresses to severe stages, suggesting that systematic treatment in PWID, where incidence 
remains high, would be beneficial. However, eradication will be difficult to achieve.  
  
4 
 
INTRODUCTION 
Hepatitis C Virus (HCV) is responsible for more than 350,000 deaths every year worldwide (1). In 
high income countries, the main HCV transmission route is injection drug use(2). In these countries, 
despite the introduction since the 80s of harm reduction measures, HCV prevalence among people 
who inject drugs (PWID) remains high,often above 60% (3). 
Until recently,HCV treatment standard of care was a dual therapy combiningpeg-interferon and 
ribavirin that was moderately effective and with a high proportion of adverse events (4, 5). New 
direct-acting antiviral (DAA) based interferon-freeregimens, associated with highersustained 
virological response (SVR) rates, better tolerance profiles, and shorter durations arenowavailable(6-
11). These therapeutic improvements raise the question of usingHCV treatment as a mean of 
preventing HCV transmission in PWID, and, in the longer-term of possibly eradicating the virus. 
However, the effectiveness of this strategy depends on several factors: time to diagnosis, patients’ 
linkage to care, and treatment initiation criteriato achieve early treatment initiation; and adherence to 
care and treatment, to achieve a high SVR rate. 
Evaluating the impact of incoming treatments or improvementsin the cascade of care on transmission 
inPWIDthrough traditional epidemiological studies faces issues related to feasibility and costs. 
Dynamic modeling of HCV transmission inPWID is an interesting alternative allowing us to estimate 
the impact of various scenarioson the spread of HCV in this population. Numerous models have been 
proposed in the literature(12). However, most of them did not considered the social network of PWID, 
which impactsviral transmission (13); and they have often estimated strategies impacting only a 
specific point in the cascade of care (and in particular treatment rate or treatment effectiveness), not 
the overall cascade. 
The aim of this analysis wasto estimate, in the context of incoming DAAs regimens, the impact of 
HCV testing, linkage to care, and treatment efficiency improvement, andof changes in treatment 
initiation criteria,on HCV transmission andHCV-related morbidityinPWID. For this purpose, we useda 
dynamic stochastic individual-based model (IBM) with a social network model of PWID and a natural 
history model of chronic hepatitis C.  
5 
 
METHODS 
Here, we present the simulated population, the structure of the model, details of the different scenarios 
we evaluated, and the sensitivity analyses we performed. More details regarding the hypotheses we 
made on parameter values are given in Supplementary Information S1. 
Population 
In this analysis, we focusedon a populationwith the characteristics of the PWIDpopulation in France. 
We considered that the size of the population was constantat 10,000 PWID – the order of magnitude of 
the drug user population in the main cities of France(14).Each PWID is characterized by 1) gender, to 
take into account differences of mortality between men and women(15): the gender of each new 
PWIDis drawn following a probability𝑝𝑀of being a man; 2) a set of injecting partners: we draw for 
each PWID a group of other PWID in the population according to a random graph model (see 
Supplementary Information S1) susceptible ofinfecting or becoming infected by the index PWID; 3) 
his/her status relating to injection: current or former injector, i.e.injector after cessation of drug use; 4) 
his/her HCV-infection status; 5) if HCV-infected, his/her status regardingHCV infection knowledge 
and linkageto care, liver fibrosis stage, and treatment.  
 
Model 
Social network of injecting partners model 
One of our objectives was to simulate possible pathways of HCV transmission in PWID. HCV is 
mainly transmitted by needles/syringes sharing in the PWID population; however paraphernalia 
sharing (e.g. filter, spoon) seems to play an important role too (16). To take into account the global 
risk of infection for a PWID, we chose, as previously described by Rolls et al., to model the network 
of the sharing partners: two PWID are linked together if they inject together even without sharing 
needles/syringes (13). 
The mathematical literature describes numerous models of networks (17). In the case of the injecting 
partners’ network, the choice of a graph model is difficult, because no data are currently available on 
PWID social networks in France. Therefore, we used an Erdős-Rényi model where each PWID 
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“couple” is linked with a fixed probability 𝑝(18). This model is simple to calibrate with only one 
parameter, which can easily be obtained with field studies: knowing𝑑 , the mean number of injecting 
partners per PWID (i.e. the degree), and 𝑁, the size of the population, the parameter of the Erdös-
Rényi model is 𝑝 = 𝑑 /𝑁.  
We assumed a static network, i.e. where there is no change in the links between PWID overtime. In 
addition, we hypothesized that each PWID who dies would be replaced by a new PWID. 
 
Transmission and care model 
We divided the population into two states: current injection injector and former injector. Each new 
PWID in the population is a current injector, and we attributed each one a duration for their injecting 
career, drawn from an exponential distribution of mean 1/𝜃, where 𝜃 is the rate of drug use cessation. 
Only current injectors can transmit HCV or be infected with HCV; we assume that sexual transmission 
of HCV in this population is negligible, as the incidence rate is approximately one per 190,000 sexual 
contacts for heterosexual relationships (19).  This mode of transmission was therefore not considered.  
Figure 1 describes the possible states through which PWID can progress. Briefly, new PWID start in S 
(Susceptible at high risk of infection) for an average duration of one year, as there is a large amount of 
data showing that PWID are at higher risk of HCV infection during the first year of their injecting 
career (20). After a time determined by the rate 𝜂, they progress to S’ (Susceptible at low risk of 
infection), in which their risk of infection is lower. In S (respectively S’), each PWID 𝑘 may be 
infected at rate 𝛽𝐼(𝑘) (respectively𝛽’𝐼(𝑘)), with 𝛽 (respectively 𝛽’) the infection rate per infected 
partner, and 𝐼(𝑘) the PWID’s number of infectious injecting partners. After infection, PWID progress 
to stage A (Acute hepatitis C), in which they stay for a fixed time 𝑇𝑎 . Acute Hepatitis C can lead to a 
spontaneous recovery with a probability 𝑝𝑟 , and the PWID returns in S’. Given the length of time 
between the beginning of the injecting career and the end of the acute hepatitis C, we did not consider 
transitions between A and S. If spontaneous recovery does not occur, PWID progress from A to UC 
(Undiagnosed Chronic hepatitis C) with a probability equal to 1− 𝑝𝑟 . A chronic hepatitis C is 
diagnosed at rate 𝛿, which depends on the status of current/former injectors. When a PWID is 
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diagnosed, he/she progress to DNLC (Diagnosed and Non-Linked to care Chronic hepatitis C). A 
PWID is considered linked to care if he/she has one or more contact per year with a health care service 
regarding his/her HCV-infection. When a PWID is linked to care with a rate 𝜙𝐿𝑖𝑛𝑘 , he/she progress 
from DNLC to DLC (Diagnosed and Linked to care Chronic hepatitis C). However, he/she can be lost-
to-follow at rate 𝜙𝐿𝑜𝑠𝑡 , and in this case the PWID returns to the DLC status. We considered that PWID 
with cirrhosis complications (i.e. decompensated cirrhosis and/or hepatocellular carcinoma (HCC), see 
“Natural history” below) are always linked to care because of the severity of their illness. 
PWID linked to care and who have a Metavir score between F2 and F4 (see subsection “Natural 
history model”) are immediately treated for chronic hepatitis C, according to French national 
guidelines in December 2014 (21), and progress to T (Treatment). Treatment has a fixed duration 𝑇𝑡 , 
and can lead to SVR with a probability 𝑝𝑆𝑉𝑅 : in this case, the PWID returns to the S’ state; he/she can 
be re-infected in the same manner as PWID who have never been infected with HCV. If the PWID 
does not respond to treatment he/she progress to the Non-SVR state with probability 1− 𝑝𝑆𝑉𝑅 . This is 
an absorbing state, i.e. a PWID cannot escape this state, as we did not include the possibility of 
retreatment. The effectiveness of the DAAs in real-life and especially in PWID is not currently 
available. We therefore broke down 𝑝𝑆𝑉𝑅  into two variables such as 𝑝𝑆𝑉𝑅 = 𝑟 × 𝑒, where 𝑒 is the 
treatment efficacy observed in clinical trials and 𝑟 is the ratio of the effectiveness of treatment in real-
life to the efficacy in clinical trials. 
In each state of our model, we applied a mortality rate for deaths unrelated to HCV infection (i.e. 
unrelated to a cirrhosis complication). This rate, denoted 𝜇, depends on two factors: the gender of the 
injector and the injector’s status (current or former injector) (15). Mortality due to hepatitis C was 
taken into account in the natural history model described below. 
 
Natural history model 
The natural history model (Figure 2) describes the liver disease progression in HCV-infected PWID. It 
describes the fibrosis progression using the Metavir Score (22): F0 = no fibrosis, F1 = portal fibrosis 
without septa, F2 = portal fibrosis with few septa,  F3 = numerous septa without cirrhosis, F4 = 
cirrhosis. In this analysis we grouped F0 and F1, and F2 and F3 in unique states (F0/F1; F2/F3). 
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The second part of the model describes cirrhosis complications. The first complication is the 
decompensated cirrhosis, and the second is HCC. In the model, decompensated cirrhosis may progress 
to HCC. Finally, those complications lead to death related to HCV-infection. 
In case of successful treatment (see previous subsection), we considered that the PWID fibrosis 
regresses to F0, except if the patient has already developed cirrhosis (F4) (23). In this case, we 
considered that cirrhosis complications may still occur (23) with the same rate as that with chronic 
hepatitis C. 
 
Input Parameters 
Input parameters were mainly derived from ANRS-Coquelicotstudydata, which was a HCV-
seroprevalencecross-sectional survey conducted among drug users in France (24), and from the 
medical literature.Missing parameters were fitted by Approximate Bayesian Computation (ABC – see 
Supplementary Information S2)(25). 
A summary of parameters and their default values are given in Supplementary Information S1, Table 
S1.  
 
Tested scenarios 
We simulated 7 scenarios, corresponding to different testing rates, linkage to care and loss to follow-
up rates, treatment initiation criteria or SVR rates(see Table 1). 
Scenario 1 (reference scenario) is the scenario with the parameter values presented in Table S1 in 
Supplementary Information, corresponding to the current cascade of care in the French PWID 
population.In the baseline analysis, for the nature of HCV treatment,we considered that patients 
receivedDAAs-based regimens. SVR for these regimens are estimated at𝑒=90% in clinical trials and 
treatment duration at 𝑇𝑡=12 weeks (6-11). However, we decreased the efficacy rate of these treatments 
since they were derived from clinical trials in mostly non-IDUs population. To make these 
modifications, we applied the coefficient 𝑟 derived from the ratio of the SVR inreal life to the SVR in 
clinical trials for peg-interferon + ribavirin(𝑟=0.903)(26). 
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Scenario 2is scenario 1 with an improvedtesting rate.The mean time between infection and testing 
(1/𝜃)is considered to be0.5 years for all individuals (vs.1.25/1.45 years for current/formerPWID under 
scenario 1). 
Scenario 3is the same as scenario1 with improved linkageto and retention incare: PWID are linked to 
care after an average duration of 0.5 years (vs. 2.6 years in scenario 1) and the loss to follow-up rate is 
5%/year (vs. 13.8%/year in scenario 1). 
Scenario 4isa combination of scenarios 2and3 (improved testing, linkage to and retentionin care). 
Scenario 5is scenario 1 with improvedadherence to treatment.We considered that a better adherence 
could lead to a SVR rate similar to that of clinical trials, i.e.;𝑟=1 (vs.0.903 in scenario 1). 
Scenario 6is scenario 1 with changes in treatment initiation criteria.All PWIDwho are tested, linked to 
care and who haveno complications of cirrhosis are treated,regardless of fibrosis stage. 
Scenario 7 is the combination of scenarios 4, 5 and 6: improved testing, linkage to and retention in 
care; earlier treatment initiation criteria; and better adherence to treatment. 
 
Implementation of the model and outcomes 
For each scenario or sensitivity analysis, we performed 1,000 simulations. To ensure that results are 
comparable and to avoid the influence of the randomness in the network or population structure, we 
matched the simulations: each scenario was simulated on the same 1,000 simulated networks 
andPWID populations. 
The impact of the scenarios on the prevalence andthe incidence at 10 years, and on the difference in 
the number of newcomplications of cirrhosis in the population after10 and 40 yearswas calculated and 
compared to the reference scenario. This time horizon for the number of cirrhosis complications was 
chosen because of the long delay before the occurrence of the complications in HCV infections.  
 
Sensitivity analysis 
We first performed a global deterministic sensitivity analysis to determine the parameters that have the 
most important impact under the reference scenario on the outcomes. We varied the values of the 
following parameters over the range of their uncertainty intervals, using data from otherhigh income 
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countries, or using estimates from expert opinion: the infection rates 𝛽’, the relative risk of infection 
during the first year of the injecting career, the testing rate 𝛿, and the linkage to care rate and lost to 
follow-up rate 𝜙𝐿𝑖𝑛𝑘  and𝜙𝐿𝑜𝑠𝑡 , the transitions rates of the natural history model, and the initial 
distribution in the natural history model (Supplementary Information S5, Table S3). 
We also performed specific sensitivity analysis about the parameters where uncertainty was important. 
First, when theparameter’sestimate was uncertain because of the data source: the average number of 
injecting partners, which was fixed at 6 by hypothesis according to limited information from other 
countries (see Supplementary Information S1, Table S1). We also varied the values of the parameter 
for which the situation could change – or had already changed – compared toour estimates: the 
infection rate 𝛽’, as some evidence from different French sociological surveys show anincreaseinat-
risk practices among PWID in France in recent years; and the risk of re-infection rate after a SVR, 
which can be higher than the primary infection rate (27, 28). Thus, we estimated the impact of a drop 
to an average of 3 partners or an increase to an average of 15 partners per PWID; and the impact of 
increasing the reference infection rate 5 (𝛽′ = 0.05) and 10 times (𝛽′ = 0.1)on all the simulated 
scenarios.  
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RESULTS 
Impact of different interventions on the HCV-prevalence, incidence andrelated complications 
Figure 3 illustrates the impact of different interventions on the HCV infection prevalence and 
incidence at 10 years, and Figure 4 the impact on the number of complicationsof cirrhosis over 10 and 
40 years. Tables S3 and S4in Supplementary Information present more details.  
The HCV viral prevalence was set at 42.8% at the beginning of the simulation. With scenario 1 
reflecting the current situation of HCV treatment, the mean prevalence decreased to 24.9% [95% 
confidence interval: 24.8%–24.9%] at 10 years. An improved testing performance (scenario 2) and/or 
linkage to care (scenario 3 and 4)or an improved adherence to treatment had a small impact on the 
results. Treating HCV-infected patients at the F0/F1 stage (scenario 6) decreased the prevalence at 10 
years to 11.6% [11.6%–11.7%]. Finally, when combiningimproved testing, linkage to care, and 
adherence to treatment (scenario 7), we obtained a prevalence of 7% [7%–7.1%].Impact on the HCV 
incidence at 10 years followed comparable trends (see Figure 3). 
Compared with the reference scenario (scenario 1),scenario 2, which includesimproved testing, had a 
small impact on the number of cirrhosis complications avoided after 10 and 40 years. Scenario 3, with 
an improved linkage to care, led to a decrease of9.8% [8.5%–11.1%] and 11.5% [10.0%–3.1%] over10 
and 40 years respectively. In scenario 5, the improved adherence to treatment led toa decrease of3.2% 
[1.8%–4.6%] and 11.7% [10.0%–13.3%]. Treating infected PWID from F0/F1stage in scenario 6 did 
not have any impact on the number of cirrhosis complications.  In scenario 7,with improved testing, 
linkage to care, adherence to treatment and early treatment the number of cirrhosis complications 
decrease was at 15.3% [14%–16.6%] and  29%; [27.9%;30.1%] over10 and 40 years respectively. 
 
Impact of different strategies on the cumulative number of treatments initiated 
The average cumulative number of treatment courses initiated during the first 10 years (Figure 5) is 
higher in scenarios 6 and 7, when HCV treatment is initiated early, with 3,978 and 4,066 treatments 
initiated, respectively,vs. scenarios 1 to 5, when treatment is initiated at liver fibrosis stages >F2, 
with2,349 and 2,404treatments initiated, respectively. In addition, the distribution of the number of 
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treatments initiated overtime is different under different scenarios. Inscenarios 3, 4, 6, and 7, more 
treatments were used at the beginning of the simulation period compared to scenarios 1,2, and 5. 
 
Sensitivity analysis 
The detailed results of the deterministic sensitivity analysis of the model under the reference scenario 
are presented in Supplementary Information S5, Figure S2. The infection rate per partner, the 
transition rate between F0/F1 and F2/F3, the linkage to care/lost to follow-up rates are the parameters 
with the most important impact on HCV prevalence at 10 years, with variations of -3.1% to +4.7%, -
2.2% to +2.6%, and -1.5% to +2.7%,respectively. The fourth parameter in order of importance is the 
average time to diagnosis, with variations of -0.2% to +2.5%. For the incidence at 10 years, the 
infection rate per partner, the average time to cessation and the relative risk of reinfection after a SVR 
are the most sensitive parameters with variations of respectively -0.6/100PY to +1.2/100PY, -
0.2/100PY to +0.1/100PY and 0/100PY to 0.3/100PY. The transition rate between F2/F3 and F4, the 
initial fibrosis distribution and the linkage to care/loss to follow-up rates are the most sensitive 
parameters regarding to the cirrhosis complications over10 years.  
In the other sensitivity analyses,results were robust to variations in the average number of injecting 
partners(3 or 15 vs. 6, see Table S4). When we increased the infection rate (see Figure S3 and S4)to 
𝛽′ × 5to take into account a possible increase in the PWID risk-taking behaviors,prevalence at 10 
years was stable in the reference scenario, varying only from 42.8% to 43.7% [43.6%–43.8%] despite 
DAA use. When we increased the infection rate to 𝛽′ × 10, the prevalence at 10 years increased to 
60.5% [60.4%–60.6%]. In these two cases, results were similar than in the basecase analysis. 
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DISCUSSION 
The proposed model allows comparing different scenarios impacting every step of the cascade of care 
(testing, linkage to care, treatment) on both the transmission of HCV and on the HCV-related 
morbidity. The results of the simulations showed several important points.  
First, improvinglinkage to careor increasing the SVR rate to match that achieved with new 
DAAsdecreased the number of cirrhosiscomplicationsby10% on average after 40 years compared to 
the current situation. The benefit is relatively fast when improving linkage to care (9.8% after 10 
years), meanwhile increasing the SVR rate had a more long-term impact. However, changing these 
parameters onlyhad a small benefit on transmission,and, therefore, on the reduction in HCV 
prevalence(less than a 2% decrease in prevalence at 10 years). Second, the impact of improved testing 
was low on both transmission and morbidity. This trend is observed because,in France, HCV testing 
rate is already high: Francehas one of the highest rate of infection awareness in Europe(29, 30).In the 
sensitivity analysis,using testing rates observed in the UK, where the time between chronic infection 
and diagnosis is estimated to be 7.8 years(vs. 1.25/1.45 years in our model), we obtained for example 
a10.4% increase of cirrhosis complications after 40 years. Thus, improved HCV testing could lead to a 
larger benefit in other settings.Third, initiatingHCV treatment earlier, at F0/F1 fibrosis stage, had an 
important impact on transmission. The impact on morbidity was relatively moderate. From an 
individual perspective, treating early is not associated with an important benefit because a large 
proportion of the infected population never develop a liver complication (31). Those who do progress 
to later HCV fibrosis stages are usually detected and treated before developing complications using 
HCV fibrosis monitoring tools.Although, in our analysis we considered that we had perfect tools, 
which may be an optimistic hypothesis(32). In contrast, from a population perspective, treating 
patients early does prevent HCV transmission.Finally, improvements in testing,linkage to care, and 
adherence to treatment in addition to early treatment initiation allowedfor a substantialdecrease inboth 
HCV transmission and morbidity. 
The current recommendations suggest treatingpatients who reached F2,because HCV treatment 
regimens are costly and a high proportion of chronic hepatitis does not lead to complications(21). 
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Themodel shows that if the objective of policy-makers is the eradication of the virus, treating PWID 
from F0, in settings where the incidence remains high, is necessary.However, even in this case, 
eradication will be difficult to achieve and only important improvements on the cascade of care 
allowed decreasing the prevalence at 10 years below 10%. 
The availability of a highly effective and well-tolerated treatment could potentially cause an increase 
in risky practices (i.e. needle sharing or some other example), as for HIV, for which the belief about 
highly active antiretroviral therapy had an impact on sexual risk behaviors, even if sexual behaviors 
and injection practices are not easily comparable due to different social practices (33). However, in our 
sensitivity analysis, we showed that our conclusions remained valid with an incidence 5 to 10 times 
greater than the base case.Since treatment regimens are expensive, the question of reinfection is an 
important one. In our model,using a re-infection rate per partner 10 times higher than the primary 
infection rate only had a low impact on the prevalence at 10 years, with less than 2% increase. 
However, the lack of data on the PWID social network in France constrained us to use a simple model 
with basic properties. Particularly, it shows no community structures (i.e.strongly linked and relatively 
isolated groups).Further data are needed to build a more sophisticated modelandclarify this important 
point. 
This study presents several limitations. First, we placed our model in an ideal setting where the 
treatment regimens are given according to the national recommendations: PWID cannot decide or be 
told to reject treatment for any reason. In real life,because of the assumedrisk of reinfection and poor 
compliance of PWID there isresistance to treatment initiation.However, with the arrival of well-
tolerated, injection-free treatments, with shorter durations, one may suppose that the treatment 
compliance will increase. Moreover, we hypothesized that there was only one line of HCV treatment 
and there was no retreatment after first treatment failure. We did not account for possible behavioral 
changes in PWID upon learning their hepatitis status (34), although they could impact the results.In 
this analysis, we did not limit the number of available treatment slots. Treating patients early 
(scenarios 6 and 7) sharply increased the cumulative amount of treatment used during the first years, 
which quickly reach 4,000 treatment courses after a few years, but remained stable thereafter.Given 
the current high costs associated with new DAAs (between 41,000 and 48,000 euros for a 12-week 
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treatment course in France), budgetary impact will be an important issue especially when we consider 
treating patients early. In addition to costs, early treatment may have an important logistical and 
organizational impact for the medical system.  
In conclusion we built an individual-based model taking into account the HCV infection, social 
network, natural history and cascade of care of chronic hepatitis C. We showed that to make the 
eradication of HCV possible, highly effective treatments are not sufficient in PWID, but an 
unconditional treatment, ideally associated with an improvement of access to care, is required. Several 
research pathways are offered by this model. In this context of costly treatment, a cost-effectiveness 
analysis should be considered in the future. In particular, we should evaluate the cost-effectiveness of 
strategies targeting PWID in the population according to their social network, that were shown to be 
more optimal in term of number of treatments needed(35). In addition, harm-reduction strategies such 
as supervised consumption rooms, improvement of needles/syringes exchange programs or 
substitution therapies, represent another way to impact the HCV epidemic. HCV treatment and care is 
not the only efficient strategy to decrease HCV transmission and the impact of these harm-reduction 
strategies along with treatment should be considered in the future to eradicate HCV infection.  
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Table 1Description of the scenarios 
Scenario 
Average time to 
diagnosis 
(current/former 
PWID) 
1/𝛿 
Average 
time to 
LTC 
1/𝜙𝐿𝑖𝑛𝑘  
Loss to 
follow-up 
rate 
𝜙𝐿𝑜𝑠𝑡  
Treatment 
initiation 
criteria 
%SVR 
𝑒 
1 
(reference) 
Incoming DAAs regimens 1.25 y / 1.45 y 2.6 y 14%/y F2 →F4 81.30% 
2 
Incoming DAAs regimens 
+ improved testing 
0.5 y 2.6 y 14%/y F2 →F4 81.30% 
3 
Incoming DAAs regimens  
+ improved LTC 
1.25 y / 1.45 y 0.5 y 5%/y F2 →F4 81.30% 
4 
Incoming DAAs regimens  
+ improvement of testing 
+ improvement of LTC 
0.5 y 0.5 y 5%/y F2 →F4 81.30% 
5 
Incoming DAAs regimens 
+ improved adherence to 
treatment 
1.25 y / 1.45 y 2.6 y 14%/y F2 →F4 90.00% 
6 
Incoming DAAs regimens 
+ earlier treatment initiation 
1.25 y / 1.45 y 2.6 y 14%/y F0 →F4 81.30% 
7 
Incoming DAAs regimens  
+ Changes in recommendations 
to treat earlier 
+ improvement of testing  
+ improvement of LTC 
+ improvement of adherence to 
treatment 
0.5 y 0.5 y 5%/y F0 →F4 90.00% 
SVR: Sustained virological response; PWID: People who inject drugs; DAA: Direct-acting antiviral; 
LTC: Linkage to care 
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Figure 1Individual-based model for HCV infection and cascade of care. S: Susceptible people at high 
risk (inexperienced injector); S’: Susceptible people at low risk (experienced injectors); A: Acute 
hepatitis C; UC: Undiagnosed chronic hepatitis C; DNLC: Diagnosed and non-linked to care with 
chronic hepatitis C; DLC: Diagnosed and linked to care with chronic hepatitis C; T: Treatment; Non-
SVR: No sustained virological response. The Greek letters correspond to annual rates and the 
transitions occur according to exponential laws. n(I) is the number of current infected injecting 
partners of the PWID. The time spent with acute hepatitis C Ta or on treatment Tt is deterministic. The 
issue of these states, UC or S’ in A, and Non-SVR or S’ in T, is determined by a Bernoulli drawn set 
of parameter prand pSVR respectively. In each state of the model, cessation of injections or death non-
related to HCV occur according to exponential laws.  
 
  
20 
 
 
Figure 2 Natural history model for chronic hepatitis C. We grouped Metavir score F0 and F1 (F0/1), 
and F2 and F3 (F2/3) for simplicity. The transitions times between the different states are drawn in 
exponential distributions. 
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Figure 3 Boxplots of the outcomes of the model according to the different scenarios. A. Prevalence at 
10 years; B. Incidence at 10 years. The black line represents the median, the box represents the 
interquartile range.Whiskers maximum distance is 1.5 times the interquartile range.  
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Figure 4Average percentage of cirrhosis complications avoided over A. 10 years and B. 40 years for 
each scenario, compared to scenario 1. 
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Figure 5Cumulative number of treatment courses initiated over the 10 years of simulations, for each 
scenario. 
 
